HCmed Innovations Co (TPE:6934) Accounts Payable: NT$10.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6934 HCmed Innovations Co Ltd TPE:6934
11 GF Score
Price NT$73.10
! 2 Warning Signs
View Full Analysis

What is HCmed Innovations Co Accounts Payable?

HCmed Innovations Co TPE:6934 +1.53% 11 Accounts Payable is NT$10.8 Mil as of Jun. 2026. GuruFocus rates TPE:6934 with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

HCmed Innovations Co's Accounts Payable for the quarter that ended in Jun. 2026 was NT$10.8 Mil.

HCmed Innovations Co's quarterly Accounts Payable increased from Dec. 2025 (NT$6.9 Mil) to Mar. 2026 (NT$7.7 Mil) and increased from Mar. 2026 (NT$7.7 Mil) to Jun. 2026 (NT$10.8 Mil).

HCmed Innovations Co's annual Accounts Payable increased from Dec. 2023 (NT$0.7 Mil) to Dec. 2024 (NT$1.3 Mil) and increased from Dec. 2024 (NT$1.3 Mil) to Dec. 2025 (NT$6.9 Mil).

HCmed Innovations Co Accounts Payable Related Terms

HCmed Innovations Co Accounts Payable Historical Data

* Premium members only.

The historical data trend for HCmed Innovations Co's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HCmed Innovations Co Accounts Payable Chart

HCmed Innovations Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
0.00 1.24 0.72 1.25 6.93

HCmed Innovations Co Quarterly Data
Dec21 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.10 5.43 6.93 7.71 10.80
TPE:6934
11GF Score
HCmed Innovations Co Ltd TPE:6934
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HCmed Innovations Co Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of NT$10.8 Mil mean?
HCmed Innovations Co (TPE:6934) has a Accounts Payable of NT$10.8 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on HCmed Innovations Co and its competitors.
Is HCmed Innovations Co's Accounts Payable too high?
HCmed Innovations Co's current Accounts Payable is NT$10.8 Mil. Overall, HCmed Innovations Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does HCmed Innovations Co's Accounts Payable compare to ABT and SYK?
HCmed Innovations Co's Accounts Payable of NT$10.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Devices & Instruments company?
A good Accounts Payable depends on the Medical Devices & Instruments industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on HCmed Innovations Co and its competitors. HCmed Innovations Co's current Accounts Payable is NT$10.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCmed Innovations Co stock overvalued right now?
HCmed Innovations Co (TPE:6934) has a current Accounts Payable of NT$10.8 Mil. The current Accounts Payable is NT$10.8 Mil. HCmed Innovations Co's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For HCmed Innovations Co (TPE:6934), the current Accounts Payable is NT$10.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HCmed Innovations Co Business Description

Address Dunhua S. Road, Rm.B, 10th floor., No.319, Sec.2, Taipei, TWN, 106033
HCmed Innovations Co Ltd is engaged in designing, developing, manufacturing and selling drug delivery system. It is focused on inhalation therapy to create integrated drug nebulizer combination products featuring nebulization therapeutic drugs that include small molecule synthetics and large molecule biologics, as either solutions, suspensions, and even difficult-to-deliver high viscosity drugs. Its product includes Pulmogine. Geographically, the company operates in America, Europe, Asian and African regions.
11GF Score

Get the complete analysis for TPE:6934

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$73.10
Price